W. Martin Kast

This study shows that immunizing SCLC mice with isoaspartylated Elavl4 after chemotherapy improves survival, mirroring the benefit seen in patients with anti-ELAVL4 antibodies.

This paper introduces NTX250, an mRNA-based immunotherapy platform for HPV-associated cancers that induces tumor regression and durable immune memory in preclinical models.

This study identifies WAVE1 and WAVE2 as mediators of actin polymerization required for HPV16 entry into epithelial cells through filopodia formation.